Interest expense • Interest expense decreased $53 million, or 8.3%, in the three months ended June 30, 2022 compared to the prior year due to lower debt in the three months ended June 30, 2022.Income tax provision • The effective income tax rate was 26.5% for the three months ended June 30, 2022 compared to 25.3% for the three months ended June 30, 2021.Interest expense • Interest expense decreased $124 million, or 9.6%, in the six months ended June 30, 2022 compared to the prior year due to lower debt in the six months ended June 30, 2022.Income tax provision • The effective income tax rate was 24.4% for the six months ended June 30, 2022 compared to 25.2% for the six months ended June 30, 2021.The decrease in the effective income tax rate was primarily due to the impact of certain discrete tax 42 items concluded in the first quarter of 2022, partially offset by basis differences on the sale of PayFlex in the six months ended June 30, 2022.(2) During the three and six months ended June 30, 2022, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of PayFlex, which the Company sold on June 1, 2022, for approximately $775 million.(3) During the three and six months ended June 30, 2021, acquisition-related integration costs relate to the Company’ s acquisition of Aetna Inc.(4) In June 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020.(6) During the six months ended June 30, 2022, the loss on assets held for sale relates to the Commercial Business reporting unit within the Health Care Benefits segment.The carrying value of the Thailand business was determined to be greater than its fair value and a loss on assets held for sale was recorded during the first quarter of 2022.Adjusted operating income • Adjusted operating income increased $217 million, or 13.4%, in the three months ended June 30, 2022 compared to the prior year primarily driven by strong underlying performance, including higher favorable development of prior-periods’ health care cost estimates in the three months ended June 30, 2022 compared to the prior year, and membership growth across all product lines.48 • Medical membership as of June 30, 2022 of 24.4 million decreased 90,000 members compared with March 31, 2022, primarily due to the decrease of approximately 266,000 members in connection with the divestiture of the Company’ s Thailand business during the second quarter of 2022.• Operating expenses increased $115 million, or 33.5%, in the three months ended June 30, 2022 compared to the prior year primarily driven by increased restructuring and business integration costs in the three months ended June 30, 2022 compared to the prior year.• The Company’ s mail choice claims processed on a 30-day equivalent basis increased 2.8% in the three months ended June 30, 2022 compared to the prior year primarily driven by net new business and the increased utilization of Maintenance Choice prescriptions.Excluding the impact of COVID-19 vaccinations, the segment’ s total generic dispensing rate was 88.8% and 89.0% in the three months ended June 30, 2022 and 2021, respectively.Operating expenses • Operating expenses increased $148 million, or 21.5%, in the six months ended June 30, 2022 compared to the prior year primarily driven by increased restructuring and business integration costs in the six months ended June 30, 2022 compared to the prior year.• The Company’ s mail choice claims processed on a 30-day equivalent basis increased 2.8% in the six months ended June 30, 2022 compared to the prior year primarily driven by net new business and the increased utilization of Maintenance Choice prescriptions.Excluding the impact of COVID-19 vaccinations, the segment’ s total generic dispensing rate was 88.8% and 89.0% in the six months ended June 30, 2022 and 2021, respectively.Excluding the impact of COVID-19 vaccinations, prescriptions filled increased 4.6% on a 30-day equivalent basis for the three months ended June 30, 2022 compared to the prior year.Excluding the impact of COVID-19 vaccinations, the segment’ s total generic dispensing rate was 89.9% and 89.5% in the three months ended June 30, 2022 and 2021, respectively.Prescriptions filled • Prescriptions filled increased 3.3% on a 30-day equivalent basis in the six months ended June 30, 2022 compared to the prior year primarily driven by increased utilization and the impact of a weaker cough, cold and flu season experienced in the prior year, partially offset by decreased COVID-19 vaccinations.Excluding the impact of COVID-19 vaccinations, the segment’ s total generic dispensing rate was 89.9% and 89.6% in the six months ended June 30, 2022 and 2021, respectively.2021 Revenues • Total revenues decreased $81 million, or 25.6%, to $236 million in the six months ended June 30, 2022 compared to the prior year primarily driven by lower net investment income from private equity investments and lower net realized capital gains in the six months ended June 30, 2022 compared to the prior year.The decrease in cash used in financing activities primarily related to lower repayments of long-term debt during the six months ended June 30, 2022 compared to the prior year, partially offset by share repurchases in the six months ended June 30, 2022.